BNP Paribas Financial Markets Raises Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

BNP Paribas Financial Markets grew its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 122.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 62,631 shares of the biopharmaceutical company’s stock after buying an additional 34,450 shares during the period. BNP Paribas Financial Markets owned approximately 0.09% of Celldex Therapeutics worth $1,583,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. EverSource Wealth Advisors LLC grew its stake in shares of Celldex Therapeutics by 215.7% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 878 shares during the period. Headlands Technologies LLC bought a new stake in shares of Celldex Therapeutics in the fourth quarter worth approximately $81,000. KBC Group NV grew its stake in shares of Celldex Therapeutics by 79.1% in the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 1,647 shares during the period. AlphaQuest LLC grew its stake in shares of Celldex Therapeutics by 171.0% in the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 2,705 shares during the period. Finally, Aquatic Capital Management LLC bought a new stake in shares of Celldex Therapeutics in the fourth quarter worth approximately $121,000.

Celldex Therapeutics Price Performance

Shares of NASDAQ CLDX opened at $20.45 on Monday. The firm has a fifty day moving average price of $18.91 and a 200-day moving average price of $22.55. The stock has a market cap of $1.36 billion, a PE ratio of -7.96 and a beta of 1.39. Celldex Therapeutics, Inc. has a 1 year low of $14.40 and a 1 year high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). The firm had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $1.08 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. On average, research analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on CLDX shares. The Goldman Sachs Group reduced their price target on shares of Celldex Therapeutics from $36.00 to $31.00 and set a “neutral” rating for the company in a research note on Friday, May 9th. Canaccord Genuity Group began coverage on shares of Celldex Therapeutics in a research report on Monday, April 28th. They set a “buy” rating and a $64.00 target price for the company. UBS Group cut their target price on shares of Celldex Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Morgan Stanley cut their target price on shares of Celldex Therapeutics from $46.00 to $43.00 and set an “overweight” rating for the company in a research report on Friday, May 9th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $53.90.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.